Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma

Bone Marrow Transplantation volume 59, pages 561–563 (2024)Cite this article

Subjects

T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma are highly heterogeneous diseases characterized by a generally poor prognosis [1,2,3,4]. The recurrence of primary disease after transplantation poses a significant challenge for these patients [5, 6]. Consequently, there exists an imperative demand for pioneering strategies to prevent relapse in individuals with T-ALL/T-cell lymphoma who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor developed domestically in China, has demonstrated remarkable anti-tumor activity and an augmented immune cell-mediated cytotoxicity against T-cell-related hematological tumors. These findings have been substantiated by experiments in vitro and in mouse models [7, 8]. Furthermore, its clinical application has confirmed both safety and efficacy [9, 10]. However, to our knowledge, there are currently no reports regarding the use of Chidamide as preemptive treatment after allo-HSCT in patients at a high risk of relapse.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Outcomes and disease distribution in patients received Chidamide preemptive treatment.

Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References

  1. Jain N, Lamb AV, O’Brien S, Ravandi F, Konopleva M, Jabbour E, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127:1863–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Marchi E, O’Connor OA. The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management. CA Cancer J Clin. 2020;70:47–70.

    Article  PubMed  Google Scholar 

  4. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Brière J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 1998;92:76–82.

    CAS  PubMed  Google Scholar 

  5. Schmitz N, Lenz G, Stelljes M. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. Blood. 2018;132:245–53.

    Article  CAS  PubMed  Google Scholar 

  6. Muranushi H, Shindo T, Hishizawa M, Tokunaga M, Wake A, Nakano N, et al. GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma. Bone marrow Transplant. 2021;56:155–66.

    Article  CAS  PubMed  Google Scholar 

  7. Gong K, Xie J, Yi H, Li W. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J. 2012;443:735–46.

    Article  CAS  PubMed  Google Scholar 

  8. Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69:901–9.

    Article  CAS  PubMed  Google Scholar 

  9. Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26:1766–71.

    Article  CAS  PubMed  Google Scholar 

  10. Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10:69.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Guo W, Cao Y, Liu J, Zheng X, Wang M, Zheng Y, et al. Chidamide maintenance therapy in high-risk T-ALL/T-LBL after allo-HSCT: a prospective, single-center, single-arm study. Bone Marrow Transplant. 2023;58:1163–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by grants from the National Key Research and Development Program of China (grant no. 2022YFA1103500) and the National Natural Science Foundation of China (grant no. 82170210).

Author information

Authors and Affiliations

  1. Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    Weihao Chen, Jimin Shi, Yi Luo, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, He Huang & Yanmin Zhao

  2. Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, 311121, China

    Jimin Shi, Yi Luo, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, He Huang & Yanmin Zhao

  3. Institute of Hematology, Zhejiang University, Hangzhou, China

    Jimin Shi, Yi Luo, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, He Huang & Yanmin Zhao

  4. Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China

    Jimin Shi, Yi Luo, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, He Huang & Yanmin Zhao

Authors
  1. Weihao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jimin Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yi Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaoyu Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lizhen Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Huarui Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. He Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yanmin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YMZ and HH designed the study. WHC collected and analyzed the data and wrote the manuscript. JMS, YL, JY, XYL, LZL and HRF contributed to patient recruitment and treatment. All authors reviewed the manuscript.

Corresponding authors

Correspondence to He Huang or Yanmin Zhao.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval

The entire study procedure was in accordance with the Declaration of Helsinki and was approved by the Ethics Review Committee of the First Affiliated Hospital of Zhejiang University (IIT20230004C). Written informed consent was obtained from each patient or parent/legal representative.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, W., Shi, J., Luo, Y. et al. Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma. Bone Marrow Transplant 59, 561–563 (2024). https://doi.org/10.1038/s41409-023-02191-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-023-02191-1

Search

Advanced search

Quick links